Tag Archives: drugs

Should “pay to delay” launch by branded pharma be considered illegal ?

An article in the International Herald Tribune (July 10,2014) titled “EU fines drug makers over generics”, describes the $450 million fine levied in Servier, a branded producer of the blood pressure drug perindopril. The company is accused of buying up … Continue reading

Posted in Global Contexts, Operations Management, Supply Chain Issues | Tagged , , , , , , , , , | Leave a comment

Achtar drug price rise from $50 to $28,000 and impact

An article in the New York Times (December 30, 2012) describes the rise in price for a vial of the anti-inflammatory drug Achtar from $50 to $28,000. But patients who cannot pay given the drug free. The drug is off … Continue reading

Posted in Service Operations, Supply Chain Issues | Tagged , , , , , , , , | Leave a comment

Should the Indian govt squeeze foreign acquisitions of its drug companies ?

A Wall Street Journal article (Sept 27, 2011) describes worries by the Indian govt regarding the future impact of foreign acquisitions of its local drug firms – Abbot buying Piramal Healthcare and Daiichi Sankyo buying Ranbaxy Labs Ltd. The worry … Continue reading

Posted in Collaboration, Global Contexts, Operations Management, Supply Chain Issues | Tagged , , , , , , | Leave a comment